Suppliers / Medac Gesellschaft für klinische Spezialpräparate mbH;

Medac Gesellschaft für klinische Spezialpräparate mbH;

Germany 2 duplicate records merged Updated 9 July 2026

Medac Gesellschaft für klinische Spezialpräparate mbH; is a finished-dose manufacturer based in Germany. It holds one active US drug master file. Its filings concentrate with AIFA (IT), MPA (SE) and INFARMED (PT). Its GMP standing is certified by ZLG (DE), US FDA and ANVISA (Brazil), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 15 May 2025 as VAI.

1
active US DMFs
0
valid CEPs
12
registered plants 2 with an FDA FEI number
711
filings across 18 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
3 of 3 confirmed
EU GMP
0 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 15 May 2025 VAI US FDA
  • 9 May 2023 VAI US FDA
  • 12 August 2021 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Wedel, United Arab Emirates Not on file
22872 Wedel, United Arab Emirates Not on file
Wedel, United Arab Emirates Not on file
WEDEL, Germany Not on file
Schleswig-Holstein, Germany Not on file
Tornesch, Germany Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Treosulfan US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
AIFA (IT) 190 None
MPA (SE) 100 None
INFARMED (PT) 88 None
FAMHP (BE) 82 None
URPL (PL) 65 None
ANSM (FR) 42 None
ZLG (DE) None 14
US FDA None 2
ANVISA (Brazil) None 1
EMA None 1

Scale

Year Revenue Exports Destinations
2025 $53.6M Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Medac Gesellschaft für klinische Spezialpräparate mbH; comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 15 May 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported